Cargando…

Dietary supplements to reduce symptom severity and duration in people with SARS-CoV-2: study protocol for a randomised, double-blind, placebo controlled clinical trial

INTRODUCTION: COVID-19 has caused morbidity, hospitalisations and deaths worldwide. Despite four approved vaccines for COVID-19 in Canada, there is still a need for effective treatments, especially for people in the community. Vaccine efficacy is not 100% and long-term efficacy is still unknown. Fur...

Descripción completa

Detalles Bibliográficos
Autores principales: Legacy, Mark, Seely, Dugald, Conte, Ellen, Psihogios, Athanasios, Ramsay, Tim, Fergusson, Dean A, Kanji, Salmaan, Simmons, John-Graydon, Wilson, Kumanan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895416/
https://www.ncbi.nlm.nih.gov/pubmed/35241474
http://dx.doi.org/10.1136/bmjopen-2021-057024
_version_ 1784662920543600640
author Legacy, Mark
Seely, Dugald
Conte, Ellen
Psihogios, Athanasios
Ramsay, Tim
Fergusson, Dean A
Kanji, Salmaan
Simmons, John-Graydon
Wilson, Kumanan
author_facet Legacy, Mark
Seely, Dugald
Conte, Ellen
Psihogios, Athanasios
Ramsay, Tim
Fergusson, Dean A
Kanji, Salmaan
Simmons, John-Graydon
Wilson, Kumanan
author_sort Legacy, Mark
collection PubMed
description INTRODUCTION: COVID-19 has caused morbidity, hospitalisations and deaths worldwide. Despite four approved vaccines for COVID-19 in Canada, there is still a need for effective treatments, especially for people in the community. Vaccine efficacy is not 100% and long-term efficacy is still unknown. Furthermore, there are challenges to herd immunity including vaccine hesitancy and underlying conditions preventing vaccination. We aim to explore if the nutrients vitamin C, vitamin D, vitamin K(2) and zinc are an effective treatment option for outpatients diagnosed with COVID-19. The primary outcome is the difference in participant-reported overall health; secondary outcomes include the effect on health status, symptom severity and duration, frequency and length of hospitalisations and mortality. METHODS AND ANALYSIS: This study is a two-arm, parallel-group, double-blind, placebo-controlled, phase III randomised controlled trial. 200 patients will be recruited remotely from COVID-19 test centres in Ottawa, Canada associated with The Ottawa Hospital. Overall health will be measured using the EuroQol Visual Assessment Scale; health status will be measured using the EuroQol 5-dimension 5-level questionnaire; symptom severity and duration will be measured using an independently developed questionnaire; analyses will use an area under the curve approach and compare mean scores using unadjusted t tests. Study data will be recorded on electronic case report forms using the Research Electronic Data Capture platform. An independent data safety and monitoring board will perform ongoing review of the study for feasibility and safety. ETHICS AND DISSEMINATION: This study has received ethical approval from the research ethics boards of the Canadian College of Naturopathic Medicine and the Ottawa Health Sciences Network, as well as regulatory approval from the Therapeutic Products Directorate and Natural and Non-Prescription Health Products Directorate of Health Canada. Results will be published in a peer-reviewed scientific journal with open access. TRIAL REGISTRATION NUMBER: NCT04780061.
format Online
Article
Text
id pubmed-8895416
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-88954162022-03-04 Dietary supplements to reduce symptom severity and duration in people with SARS-CoV-2: study protocol for a randomised, double-blind, placebo controlled clinical trial Legacy, Mark Seely, Dugald Conte, Ellen Psihogios, Athanasios Ramsay, Tim Fergusson, Dean A Kanji, Salmaan Simmons, John-Graydon Wilson, Kumanan BMJ Open Complementary Medicine INTRODUCTION: COVID-19 has caused morbidity, hospitalisations and deaths worldwide. Despite four approved vaccines for COVID-19 in Canada, there is still a need for effective treatments, especially for people in the community. Vaccine efficacy is not 100% and long-term efficacy is still unknown. Furthermore, there are challenges to herd immunity including vaccine hesitancy and underlying conditions preventing vaccination. We aim to explore if the nutrients vitamin C, vitamin D, vitamin K(2) and zinc are an effective treatment option for outpatients diagnosed with COVID-19. The primary outcome is the difference in participant-reported overall health; secondary outcomes include the effect on health status, symptom severity and duration, frequency and length of hospitalisations and mortality. METHODS AND ANALYSIS: This study is a two-arm, parallel-group, double-blind, placebo-controlled, phase III randomised controlled trial. 200 patients will be recruited remotely from COVID-19 test centres in Ottawa, Canada associated with The Ottawa Hospital. Overall health will be measured using the EuroQol Visual Assessment Scale; health status will be measured using the EuroQol 5-dimension 5-level questionnaire; symptom severity and duration will be measured using an independently developed questionnaire; analyses will use an area under the curve approach and compare mean scores using unadjusted t tests. Study data will be recorded on electronic case report forms using the Research Electronic Data Capture platform. An independent data safety and monitoring board will perform ongoing review of the study for feasibility and safety. ETHICS AND DISSEMINATION: This study has received ethical approval from the research ethics boards of the Canadian College of Naturopathic Medicine and the Ottawa Health Sciences Network, as well as regulatory approval from the Therapeutic Products Directorate and Natural and Non-Prescription Health Products Directorate of Health Canada. Results will be published in a peer-reviewed scientific journal with open access. TRIAL REGISTRATION NUMBER: NCT04780061. BMJ Publishing Group 2022-03-03 /pmc/articles/PMC8895416/ /pubmed/35241474 http://dx.doi.org/10.1136/bmjopen-2021-057024 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Complementary Medicine
Legacy, Mark
Seely, Dugald
Conte, Ellen
Psihogios, Athanasios
Ramsay, Tim
Fergusson, Dean A
Kanji, Salmaan
Simmons, John-Graydon
Wilson, Kumanan
Dietary supplements to reduce symptom severity and duration in people with SARS-CoV-2: study protocol for a randomised, double-blind, placebo controlled clinical trial
title Dietary supplements to reduce symptom severity and duration in people with SARS-CoV-2: study protocol for a randomised, double-blind, placebo controlled clinical trial
title_full Dietary supplements to reduce symptom severity and duration in people with SARS-CoV-2: study protocol for a randomised, double-blind, placebo controlled clinical trial
title_fullStr Dietary supplements to reduce symptom severity and duration in people with SARS-CoV-2: study protocol for a randomised, double-blind, placebo controlled clinical trial
title_full_unstemmed Dietary supplements to reduce symptom severity and duration in people with SARS-CoV-2: study protocol for a randomised, double-blind, placebo controlled clinical trial
title_short Dietary supplements to reduce symptom severity and duration in people with SARS-CoV-2: study protocol for a randomised, double-blind, placebo controlled clinical trial
title_sort dietary supplements to reduce symptom severity and duration in people with sars-cov-2: study protocol for a randomised, double-blind, placebo controlled clinical trial
topic Complementary Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895416/
https://www.ncbi.nlm.nih.gov/pubmed/35241474
http://dx.doi.org/10.1136/bmjopen-2021-057024
work_keys_str_mv AT legacymark dietarysupplementstoreducesymptomseverityanddurationinpeoplewithsarscov2studyprotocolforarandomiseddoubleblindplacebocontrolledclinicaltrial
AT seelydugald dietarysupplementstoreducesymptomseverityanddurationinpeoplewithsarscov2studyprotocolforarandomiseddoubleblindplacebocontrolledclinicaltrial
AT conteellen dietarysupplementstoreducesymptomseverityanddurationinpeoplewithsarscov2studyprotocolforarandomiseddoubleblindplacebocontrolledclinicaltrial
AT psihogiosathanasios dietarysupplementstoreducesymptomseverityanddurationinpeoplewithsarscov2studyprotocolforarandomiseddoubleblindplacebocontrolledclinicaltrial
AT ramsaytim dietarysupplementstoreducesymptomseverityanddurationinpeoplewithsarscov2studyprotocolforarandomiseddoubleblindplacebocontrolledclinicaltrial
AT fergussondeana dietarysupplementstoreducesymptomseverityanddurationinpeoplewithsarscov2studyprotocolforarandomiseddoubleblindplacebocontrolledclinicaltrial
AT kanjisalmaan dietarysupplementstoreducesymptomseverityanddurationinpeoplewithsarscov2studyprotocolforarandomiseddoubleblindplacebocontrolledclinicaltrial
AT simmonsjohngraydon dietarysupplementstoreducesymptomseverityanddurationinpeoplewithsarscov2studyprotocolforarandomiseddoubleblindplacebocontrolledclinicaltrial
AT wilsonkumanan dietarysupplementstoreducesymptomseverityanddurationinpeoplewithsarscov2studyprotocolforarandomiseddoubleblindplacebocontrolledclinicaltrial